Comparative Pharmacology
Head-to-head clinical analysis: BREVITAL SODIUM versus SURITAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVITAL SODIUM versus SURITAL.
BREVITAL SODIUM vs SURITAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brevital sodium (methohexital) is a barbiturate that acts as a GABA-A receptor agonist, enhancing chloride ion influx and hyperpolarizing neurons, leading to rapid sedation and anesthesia.
SURITAL (thiamylal) is an ultra-short-acting barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization, resulting in rapid induction of anesthesia.
Induction of anesthesia: 1-1.5 mg/kg IV bolus over 15 seconds; maintenance: 0.5-1 mg/kg IV bolus as needed or 50-150 mcg/kg/min IV infusion.
Induction: 3-5 mg/kg IV bolus over 10-15 seconds. Maintenance: 0.5-1.5 mg/kg IV as needed for anesthesia. Also used as 0.2-0.4% solution for IV infusion at 0.5-2 mg/min.
None Documented
None Documented
Terminal elimination half-life: 3–6 hours (mean ~4 hours); prolonged in hepatic impairment, obesity, or with repeated dosing due to redistribution.
Terminal elimination half-life 2-8 hours (mean 4.5 h) in adults; prolonged in hepatic impairment.
Primarily hepatic biotransformation to inactive metabolites (mainly hydroxy-methohexital), with renal excretion of metabolites; less than 1% excreted unchanged in urine. Minor biliary/fecal elimination.
Primarily renal excretion of metabolites; <1% unchanged. Minor biliary/fecal elimination.
Category C
Category C
Barbiturate Anesthetic
Barbiturate Anesthetic